The latest report by IMARC Group titled, “Global Biopharmaceutical Manufacturing Market Report 2017-2021”, finds that the global biopharmaceutical manufacturing capacity has grown at a CAGR of more than 4% during 2009-2016, reaching a volume of around 4.5 Million Litres in 2016. Biopharmaceuticals currently represent the fastest growing segment in the global pharmaceuticals market on account of their various health benefits. The high returns associated with their production has also prompted a number of companies to develop and manufacture biopharmaceutical drugs. Moreover, the emergence of biosimilars coupled with capacity expansions are further expected to bolster the market growth. According to the report, the global biopharmaceutical manufacturing market is projected to reach a volume of 6.6 Million Litres by 2021.
Highlights of the Global Biopharmaceutical Manufacturing Market:
- Continuous improvements in technology and growth in outsourcing activities remain the major drivers.
- Mammalian cell culture represents the largest category, accounting for the majority of production volume.
- North America dominates the market, accounting for nearly half of the market share.
Request a free sample copy of the report: http://www.imarcgroup.com/request?type=report&id=724&flag=B
One of the major trends in the market is the continuous improvement in technology aimed at increasing productivity. Manufacturers are focusing on processes such as continuous bioprocessing and the use of single-use or disposable devices so as to increase the yield. Moreover, owing to the significant cost savings and effectiveness as well as innovation and specific capabilities offered by the contract manufacturers, a number of companies are outsourcing various production activities to them. The contract manufacturers carry out activities ranging from the analytical testing of bioassays to testing the cell line stability and product characterisation. A large number of contract manufacturers are based in emerging regions such China and India which are progressively becoming a major destination for outsourcing.
On the basis of the cell culture, the market has been divided into mammalian and microbial cell cultures. Mammalian cell culture currently represents the largest category, accounting for the majority of the production volume. This can be attributed to the large number of drugs which are made using mammalian cell cultivation. On the basis of class, the market has been segmented into recombinant proteins, monoclonal antibodies, interferons, erythropoietin, granulocyte colony-stimulating factor (G-CSF), recombinant human insulin, vaccines and human growth hormones (HGH). On the basis of region, North America currently represents the largest market, accounting for nearly half of the total market share. Some of the key players operating in the market include Biogen Idec, Roche, Eli Lilly, Amgen, Merck & Co., Novo Nordisk, Pfizer, AbbVie, Sanofi S.A and Johnson & Johnson.
Click here for summary of the report with TOC: http://www.imarcgroup.com/global-biopharmaceutical-manufacturing-market
The report by IMARC Group has examined the global biopharmaceutical manufacturing market on the basis of:
- Mammalian Cell Culture
- Microbial Cell Culture
- Monoclonal Antibodies
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Recombinant Human Insulin
- Human Growth Hormones
- North America
- Novo Nordisk
- Sanofi SA
- Johnson & Johnson
- Merck & Co.
- Ely Lilly
- Biogen Idec
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.